Drug update

High-dose quadrivalent influenza vaccine for older populations

Drug update

High-dose quadrivalent influenza vaccine for older populations

MADELINE VALERI, ZHICHENG WANG, LUCY ARMSTRONG, BETTE LIU

Figures

© JACOBLUND/istock.photo.com model used for illustrative purposes only
© JACOBLUND/istock.photo.com model used for illustrative purposes only

Abstract

A high-dose quadrivalent influenza vaccine (Fluzone High-Dose Quadrivalent) is available on the private market in Australia in 2022 for adults aged 60 years and older. It contains four times the antigen content of standard influenza vaccines and has higher effectiveness in people aged 65 years and older while maintaining an acceptable safety profile. It also has comparable effectiveness and safety to the adjuvanted influenza vaccine in this age group.

Article Extract

Influenza is a seasonal infectious disease that usually circulates in the colder months, between April and October in Australia. Most people recover from influenza without serious illness; however, older adults, young children, pregnant women and people with certain chronic medical conditions are at higher risk of developing serious complications.1 Influenza-associated mortality rates are highest among adults aged 65 years and older.1,2